Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss new data from a pre-specified expanded dataset analysis of the company’s Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma, the most common form of skin cancer. Bokhari explained that the additional analysis builds on previously reported positive topline results, offering deeper biological, histologic, and safety insights that further strengthen the therapeutic profile of the company’s SkinJect platform. He noted that the findings are consistent with earlier clinical data, including results from the Phase 1 SKNJCT-001 study conducted in 2021 and interim Phase 2 data reported in March 2025, reinforcing the reproducibility and reliability of the treatment approach across multiple studies. The SKNJCT-003 trial was designed as a randomized, double-blind, three-arm Phase 2 study evaluating two different dose levels of microneedle-delivered doxorubicin compared to a device-only control. Conducted across multiple clinical sites, the study enrolled approximately 90 patients diagnosed with nodular basal cell carcinoma, aiming to assess both safety and efficacy in a controlled setting. According to Bokhari, the expanded dataset—verified through centralized pathology review—provides a clearer and more clinically meaningful picture of treatment outcomes. Among the cohorts, the 200-microgram dose at Day 57 emerged as the most promising, demonstrating the strongest and most consistent efficacy signal. These results suggest that the treatment may offer a non-surgical alternative for certain patients, potentially reducing or delaying the need for immediate excision of cancerous lesions. Such an approach could represent a meaningful shift in the standard treatment paradigm for BCC, particularly given the relatively short treatment and evaluation window used in the study. Bokhari added that the data package could support future registration-focused discussions with the U.S. Food and Drug Administration (FDA), including considerations around optimal dosing, patient selection, lesion subtype, and treatment timelines. The company believes these findings position SkinJect as a potentially innovative and practical therapeutic option in the dermatologic oncology space. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #Oncology #MedicalInnovation #Healthcare #FDA #Biopharma